BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31769737)

  • 21. CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges.
    Harrer DC; Dörrie J; Schaft N
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31779130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy.
    Pellegatta S; Savoldo B; Di Ianni N; Corbetta C; Chen Y; Patané M; Sun C; Pollo B; Ferrone S; DiMeco F; Finocchiaro G; Dotti G
    Sci Transl Med; 2018 Feb; 10(430):. PubMed ID: 29491184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptors.
    Kropp KN; Fatho M; Huduti E; Faust M; Lübcke S; Lennerz V; Paschen A; Theobald M; Wölfel T; Wölfel C
    Front Immunol; 2023; 14():1245559. PubMed ID: 37849763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas.
    Schiffer D; Mellai M; Boldorini R; Bisogno I; Grifoni S; Corona C; Bertero L; Cassoni P; Casalone C; Annovazzi L
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30213051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CSPG4 in cancer: multiple roles.
    Wang X; Wang Y; Yu L; Sakakura K; Visus C; Schwab JH; Ferrone CR; Favoino E; Koya Y; Campoli MR; McCarthy JB; DeLeo AB; Ferrone S
    Curr Mol Med; 2010 Jun; 10(4):419-29. PubMed ID: 20455858
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Aglas L; Bethanis A; Chrusciel P; Stolz F; Gruen M; Jaakkola UM; Jongejan L; Yatkin E; Van Ree R
    Front Immunol; 2020; 11():2118. PubMed ID: 33013894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diversified expression of NG2/CSPG4 isoforms in glioblastoma and human foetal brain identifies pericyte subsets.
    Girolamo F; Dallatomasina A; Rizzi M; Errede M; Wälchli T; Mucignat MT; Frei K; Roncali L; Perris R; Virgintino D
    PLoS One; 2013; 8(12):e84883. PubMed ID: 24386429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.
    Beard RE; Zheng Z; Lagisetty KH; Burns WR; Tran E; Hewitt SM; Abate-Daga D; Rosati SF; Fine HA; Ferrone S; Rosenberg SA; Morgan RA
    J Immunother Cancer; 2014; 2():25. PubMed ID: 25197555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chondroitin sulfate proteoglycan protein is stimulated by interleukin 11 and promotes endometrial epithelial cancer cell proliferation and migration.
    Winship A; Van Sinderen M; Heffernan-Marks A; Dimitriadis E
    Int J Oncol; 2017 Mar; 50(3):798-804. PubMed ID: 28098860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma.
    Hoffmann RM; Crescioli S; Mele S; Sachouli E; Cheung A; Chui CK; Andriollo P; Jackson PJM; Lacy KE; Spicer JF; Thurston DE; Karagiannis SN
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32331483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma.
    Mayayo SL; Prestigio S; Maniscalco L; Rosa G; Aricò A; Maria R; Cavallo F; Ferrone S; Buracco P; Iussich S
    Vet J; 2011 Nov; 190(2):e26-e30. PubMed ID: 21482159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Developmentally regulated expression of a brain specific species of chondroitin sulfate proteoglycan, neurocan, identified with a monoclonal antibody IG2 in the rat cerebrum.
    Oohira A; Matsui F; Watanabe E; Kushima Y; Maeda N
    Neuroscience; 1994 May; 60(1):145-57. PubMed ID: 8052408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia.
    Harrer DC; Schuler G; Dörrie J; Schaft N
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31195686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response.
    Boudin L; de Nonneville A; Finetti P; Mescam L; Le Cesne A; Italiano A; Blay JY; Birnbaum D; Mamessier E; Bertucci F
    J Transl Med; 2022 Oct; 20(1):464. PubMed ID: 36221119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Large-Scale Purification of r28M: A Bispecific scFv Antibody Targeting Human Melanoma Produced in Transgenic Cattle.
    Spiesberger K; Paulfranz F; Egger A; Reiser J; Vogl C; Rudolf-Scholik J; Mayrhofer C; Grosse-Hovest L; Brem G
    PLoS One; 2015; 10(10):e0140471. PubMed ID: 26469402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
    Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
    J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CSPG4: a prototype oncoantigen for translational immunotherapy studies.
    Rolih V; Barutello G; Iussich S; De Maria R; Quaglino E; Buracco P; Cavallo F; Riccardo F
    J Transl Med; 2017 Jul; 15(1):151. PubMed ID: 28668095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand.
    Amoury M; Bauerschlag D; Zeppernick F; von Felbert V; Berges N; Di Fiore S; Mintert I; Bleilevens A; Maass N; Bräutigam K; Meinhold-Heerlein I; Stickeler E; Barth S; Fischer R; Hussain AF
    Oncotarget; 2016 Aug; 7(34):54925-54936. PubMed ID: 27448975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.
    Vincent M; Bessard A; Cochonneau D; Teppaz G; Solé V; Maillasson M; Birklé S; Garrigue-Antar L; Quéméner A; Jacques Y
    Int J Cancer; 2013 Aug; 133(3):757-65. PubMed ID: 23354868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation of a monoclonal antibody against avian small dermatan sulfate proteoglycan: immunolocalization and tissue distribution of PG-II (decorin) in embryonic tissues.
    Lennon DP; Carrino DA; Baber MA; Caplan AI
    Matrix; 1991 Dec; 11(6):412-27. PubMed ID: 1787833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.